查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1933350

全球成人疫苗市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的考量因素以及未来预测（2026-2034）

Adults Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 220 Pages | 商品交期: 请询问到货日

价格

成人疫苗市场成长因素

受成人传染病发病率上升、人口老化以及成人疫苗接种意识增强等因素的推动，全球成人疫苗市场正经历强劲增长。根据 Fortune Business Insights 预测，到 2025 年，全球成人疫苗市场规模预计将达到 420.6 亿美元。预计该市场将从 2026 年的 452.2 亿美元成长到 2034 年的 1,064.3 亿美元，预测期内复合年增长率 (CAGR) 为 11.29%。北美地区凭藉较高的疫苗接种率和先进的医疗保健基础设施，在 2025 年将以 48.16% 的市占率领先。

成人疫苗接种在保护个人和社区免受严重甚至危及生命的疾病侵害方面发挥着至关重要的作用。随着年龄增长，免疫功能逐渐下降，成人更容易感染流感、肺炎、肝炎和带状疱疹等传染病。医疗关注度的提高、强有力的政府政策以及疫苗平台技术的进步，持续推动市场扩张。

市场动态

市场驱动因素

成人传染病发生率的上升是市场成长的主要驱动因素。生活方式的改变、抗菌素抗药性、人口老化以及慢性病盛行率的增加等因素都导致了感染率的上升，从而显着增加了对预防性疫苗的需求。例如，根据美国疾病管制与预防中心 (CDC) 于 2024 年 8 月发布的数据，美国 18 至 64 岁成年人中每年有超过 8.8% 的人感染流感，这凸显了成人疫苗接种计画的必要性。

市场限制因子

疫苗犹豫和错误讯息仍是限制市场成长的主要因素。透过社群媒体平台传播的误导性讯息会对大众对疫苗的信任产生负面影响。在某些地区，文化和宗教信仰也会进一步影响疫苗接种决定。根据2024年11月发表的一篇医学期刊文章，约有38.4%的成年人对接种新冠疫苗持犹豫态度，可能会限制预测期内的市场扩张。

市场机会

疫苗研发领域的技术进步带来了巨大的成长机会。 mRNA平台和新型製剂的应用提高了疫苗的有效性和安全性。这些进步有望提高成人疫苗接种率并减轻疾病负担。 2025年5月，Moderna宣布其mRNA平台可应用于传染病、免疫肿瘤和自体免疫疾病的疫苗研发，凸显了其未来的成长潜力。

市场挑战

成人疫苗接种意识不足仍然是一个重大挑战，尤其是在新兴经济体。对疫苗益处和安全性的认知不足往往会导致接种延迟或不接种。葛兰素史克公司 (GSK plc) 于 2025 年 2 月进行的一项调查发现，超过 56.6% 的 50 岁及以上印度受访者不了解带状疱疹（疱疹病毒感染），这可能会阻碍疫苗的普及。

成人疫苗市场趋势

联合疫苗的研发已成为显着的市场趋势。联合疫苗减少了所需的注射次数，提高了接种的便利性和依从性。预计流感、新冠病毒和呼吸道合胞病毒 (RSV) 的联合疫苗将越来越受欢迎。此外，世界各国政府正在根据世界卫生组织 (WHO) 的建议，采取终身接种策略，这将支持市场的长期成长。

依细分市场分析

依类型划分，重组/结合/次单位疫苗细分市场在2024年占市场主导地位，这主要得益于其高效性和长期免疫保护。灭活疫苗细分市场也占了相当大的占有率，这得益于其广泛的疾病覆盖范围和成本效益。

依给药途径划分，肠外给药细分市场在2024年占市场主导地位，这主要得益于其高生物利用度和快速起效。口服细分市场预计将稳定成长，这主要归功于其给药便利性和安全性提高。

依疾病划分，病毒性疾病细分市场在2024年占市场主导地位，这主要得益于流感、肝炎和带状疱疹的高发生率。由于人们对抗菌素抗药性的日益关注，细菌性疾病细分市场也做出了显着贡献。

依分销管道划分，政府供应商在2024年占市场主导地位，这得益于大规模疫苗接种计划和国际采购举措。

区域展望

北美地区拥有强大的疫苗接种基础设施和有利的监管框架，预计将引领市场，2025年市场规模将达到194.5亿美元，2026年将达到209.2亿美元。

欧洲由于政府支出高且积极的疫苗研发举措，占了较大的市场占有率。

亚太地区是成长最快的地区，这主要得益于高疾病盛行率、不断扩大的疫苗接种计画和日益活跃的研发活动。

拉丁美洲以及中东和非洲地区预计将保持稳定成长，这得益于人们对先进疫苗的认识和需求不断提高。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键考虑因素

  • 主要国家/地区主要疾病的发生率/盛行率（2025 年）
  • 成人疫苗的技术进步
  • 主要公司的新产品发布
  • 主要公司的研发管线分析
  • 主要产业趋势：併购、业务合作等等。

第五章 全球成人疫苗市场分析、洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依类型划分
    • 重组/结合/次单位疫苗
    • 灭活​​疫苗
    • mRNA疫苗
    • 病毒载体疫苗
    • 减毒活疫苗
    • 类毒素疫苗
    • 其他
  • 市场分析、洞察与预测：依给药途径划分
    • 肠外给药
    • 口服
  • 市场分析、洞察与预测：依疾病划分
    • 病毒性疾病
      • 肝炎
      • 流感
      • 人类用疫苗皮洛马病毒
      • 带状疱疹
      • 其他
    • 细菌性疾病
      • 脑膜炎双球菌感染
      • 肺炎链球菌感染
      • 白喉、破伤风和百日咳
      • 其他
  • 市场分析、洞察与预测：依销售管道划分
    • 医院和零售药局
    • 政府供应商
    • 其他
  • 市场分析、洞察与预测：依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章 北美成人疫苗市场分析：洞察与预测 （2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第七章：欧洲成人疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪的纳维亚
    • 欧洲其他地区

第八章：亚太地区成人疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 东南亚亚洲
    • 亚太其他地区

第九章：拉丁美洲成人疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章：中东与非洲成人疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 海湾合作委员会（GCC）成员国
    • 南非
    • 中东和非洲其他地区

第十一章 竞争分析

  • 全球市占率分析（2025）
  • 公司型材
    • Bavarian Nordic
    • GSK plc
    • EMERGENT
    • Merck &Co., Inc.
    • Inovio Pharmaceuticals, Inc.
    • Pfizer Inc.
    • Sanofi
    • CSL
    • AstraZeneca
Product Code: FBI113663

Growth Factors of adults vaccines Market

The global adults vaccines market is experiencing strong growth, supported by the rising burden of infectious diseases among adults, increasing geriatric population, and growing awareness regarding adult immunization. According to Fortune Business Insights, the global adults vaccines market was valued at USD 42.06 billion in 2025. The market is projected to grow from USD 45.22 billion in 2026 to USD 106.43 billion by 2034, registering a CAGR of 11.29% during the forecast period. In 2025, North America dominated the market with a share of 48.16%, driven by high vaccine uptake and advanced healthcare infrastructure.

Adult vaccination plays a critical role in protecting individuals and communities from serious and life-threatening diseases. As immune function declines with age, adults become more vulnerable to infections such as influenza, pneumonia, hepatitis, and shingles. The growing focus on preventive healthcare, along with strong government initiatives and technological advancements in vaccine platforms, continues to support market expansion.

Market Dynamics

Market Drivers

The increasing incidence of infectious diseases among adults is a major driver of market growth. Factors such as lifestyle changes, antimicrobial resistance, aging populations, and rising prevalence of chronic conditions have contributed to higher infection rates. This has significantly increased the demand for preventive vaccines. For instance, data published by the Centers for Disease Control and Prevention in August 2024 highlighted that influenza affects more than 8.8% of adults aged 18-64 annually in the U.S., underlining the growing need for adult vaccination programs.

Market Restraints

Vaccine hesitancy and misinformation remain key restraints for market growth. Misleading information shared through social media platforms has negatively impacted public trust in vaccines. Cultural and religious beliefs further influence vaccination decisions in certain regions. According to a medical journal published in November 2024, nearly 38.4% of adults expressed hesitancy toward COVID-19 vaccination, which may limit market expansion during the forecast period.

Market Opportunities

Technological advancements in vaccine development present significant growth opportunities. The adoption of mRNA platforms and novel formulations has improved vaccine efficacy and safety profiles. These advancements are expected to increase adult vaccination rates and reduce disease burden. In May 2025, Moderna announced that its mRNA platform could be applied to develop vaccines for infectious diseases, immuno-oncology, and autoimmune conditions, highlighting future growth potential.

Market Challenges

Lack of awareness regarding adult vaccination remains a critical challenge, particularly in emerging economies. Insufficient knowledge about vaccine benefits and safety often leads to delayed or missed immunizations. In February 2025, a survey conducted by GSK plc. revealed that over 56.6% of Indian participants aged 50 years and above were unaware of shingles disease, which may hinder vaccine adoption.

Adults Vaccines Market Trends

The development of combination vaccines has emerged as a prominent market trend. Combination vaccines reduce the number of injections required, improving convenience and compliance. Vaccines combining influenza, COVID-19, and RSV are expected to gain traction in the future. Additionally, governments worldwide are adopting life-course immunization strategies aligned with World Health Organization recommendations, supporting long-term market growth.

Segmentation Analysis

By type, the recombinant/conjugate/subunit segment dominated the market in 2024, driven by high efficacy and long-term immune protection. The inactivated vaccines segment also held a significant share due to its broad disease coverage and cost-effectiveness.

By route of administration, the parenteral segment led the market in 2024, supported by high bioavailability and rapid onset of action. The oral segment is expected to grow steadily due to ease of administration and improved safety.

By disease indication, the viral diseases segment dominated the market in 2024, driven by the high prevalence of influenza, hepatitis, and herpes zoster. The bacterial diseases segment also contributed notably due to rising concerns related to antimicrobial resistance.

By distribution channel, government suppliers dominated the market in 2024, supported by large-scale vaccination programs and global procurement initiatives.

Regional Outlook

North America led the market with a valuation of USD 19.45 billion in 2025 and USD 20.92 billion in 2026, supported by strong immunization infrastructure and favorable regulatory frameworks.

Europe held a significant share due to high government spending and active vaccine R&D initiatives.

Asia Pacific is the fastest-growing region, driven by high disease prevalence, expanding immunization programs, and increasing R&D activities.

Latin America and the Middle East & Africa are expected to grow steadily due to rising awareness and demand for advanced vaccines.

Competitive Landscape

The global adults vaccines market is concentrated, with GSK plc., Sanofi, and Serum Institute of India Pvt. Ltd. holding significant market shares. These companies benefit from strong vaccine portfolios, global distribution networks, and continuous product innovation. Other key players include Merck & Co., Inc., Pfizer Inc., AstraZeneca, Bavarian Nordic, and EMERGENT, which continue to invest heavily in research and development.

Conclusion

The global adults vaccines market is poised for robust growth throughout the forecast period, driven by the rising incidence of infectious diseases, expanding geriatric population, and increasing emphasis on preventive healthcare. With the market valued at USD 42.06 billion in 2025, projected to grow to USD 45.22 billion in 2026 and reach USD 106.43 billion by 2034, advancements in vaccine technology, growing government support, and strong industry pipelines are expected to shape the future of adult immunization. Despite challenges related to vaccine hesitancy and awareness gaps, sustained innovation and global immunization initiatives are anticipated to support long-term market expansion.

Segmentation By Type

  • Recombinant/Conjugate/Subunit
  • Inactivated
  • mRNA
  • Viral Vector
  • Live Attenuated
  • Toxoid
  • Others

By Route of Administration

  • Parenteral
  • Oral

By Disease Indication

  • Viral Diseases
    • Hepatitis
    • Influenza
    • Human Papillomavirus
    • Herpes Zoster
    • Others
  • Bacterial Diseases
    • Meningococcal Disease
    • Pneumococcal Disease
    • Diphtheria/Tetanus/Pertussis
    • Others

By Distribution Channel

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

By Region

  • North America (By Type, Route of Administration, Disease Indication, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Type, Route of Administration, Disease Indication, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Type, Route of Administration, Disease Indication, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Type, Route of Administration, Disease Indication, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Type, Route of Administration, Disease Indication, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Incidence/Prevalence of Key Diseases, By Key Countries/Regions, 2025
  • 4.2. Technological Advancements in the Adults Vaccines
  • 4.3. New Product Launches, By Key Players
  • 4.4. Pipeline Analysis, By Key Players
  • 4.5. Key Industry Developments Such as Mergers, Acquisitions, and Partnerships

5. Global Adults Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Recombinant/Conjugate/Subunit
    • 5.1.2. Inactivated
    • 5.1.3. mRNA
    • 5.1.4. Viral Vector
    • 5.1.5. Live Attenuated
    • 5.1.6. Toxoid
    • 5.1.7. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Parenteral
    • 5.2.2. Oral
  • 5.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 5.3.1. Viral Diseases
      • 5.3.1.1. Hepatitis
      • 5.3.1.2. Influenza
      • 5.3.1.3. Human Papillomavirus
      • 5.3.1.4. Herpes Zoster
      • 5.3.1.5. Others
    • 5.3.2. Bacterial Diseases
      • 5.3.2.1. Meningococcal Disease
      • 5.3.2.2. Pneumococcal Disease
      • 5.3.2.3. Diphtheria/Tetanus/Pertussis
      • 5.3.2.4. Others
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital & Retail Pharmacies
    • 5.4.2. Government Suppliers
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Adults Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Recombinant/Conjugate/Subunit
    • 6.1.2. Inactivated
    • 6.1.3. mRNA
    • 6.1.4. Viral Vector
    • 6.1.5. Live Attenuated
    • 6.1.6. Toxoid
    • 6.1.7. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Parenteral
    • 6.2.2. Oral
  • 6.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 6.3.1. Viral Diseases
      • 6.3.1.1. Hepatitis
      • 6.3.1.2. Influenza
      • 6.3.1.3. Human Papillomavirus
      • 6.3.1.4. Herpes Zoster
      • 6.3.1.5. Others
    • 6.3.2. Bacterial Diseases
      • 6.3.2.1. Meningococcal Disease
      • 6.3.2.2. Pneumococcal Disease
      • 6.3.2.3. Diphtheria/Tetanus/Pertussis
      • 6.3.2.4. Others
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital & Retail Pharmacies
    • 6.4.2. Government Suppliers
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Adults Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Recombinant/Conjugate/Subunit
    • 7.1.2. Inactivated
    • 7.1.3. mRNA
    • 7.1.4. Viral Vector
    • 7.1.5. Live Attenuated
    • 7.1.6. Toxoid
    • 7.1.7. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Parenteral
    • 7.2.2. Oral
  • 7.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 7.3.1. Viral Diseases
      • 7.3.1.1. Hepatitis
      • 7.3.1.2. Influenza
      • 7.3.1.3. Human Papillomavirus
      • 7.3.1.4. Herpes Zoster
      • 7.3.1.5. Others
    • 7.3.2. Bacterial Diseases
      • 7.3.2.1. Meningococcal Disease
      • 7.3.2.2. Pneumococcal Disease
      • 7.3.2.3. Diphtheria/Tetanus/Pertussis
      • 7.3.2.4. Others
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital & Retail Pharmacies
    • 7.4.2. Government Suppliers
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.5.1. U.K.
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Spain
    • 7.5.5. Italy
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Adults Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Recombinant/Conjugate/Subunit
    • 8.1.2. Inactivated
    • 8.1.3. mRNA
    • 8.1.4. Viral Vector
    • 8.1.5. Live Attenuated
    • 8.1.6. Toxoid
    • 8.1.7. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Parenteral
    • 8.2.2. Oral
  • 8.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 8.3.1. Viral Diseases
      • 8.3.1.1. Hepatitis
      • 8.3.1.2. Influenza
      • 8.3.1.3. Human Papillomavirus
      • 8.3.1.4. Herpes Zoster
      • 8.3.1.5. Others
    • 8.3.2. Bacterial Diseases
      • 8.3.2.1. Meningococcal Disease
      • 8.3.2.2. Pneumococcal Disease
      • 8.3.2.3. Diphtheria/Tetanus/Pertussis
      • 8.3.2.4. Others
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital & Retail Pharmacies
    • 8.4.2. Government Suppliers
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.5.1. Japan
    • 8.5.2. China
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Adults Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Recombinant/Conjugate/Subunit
    • 9.1.2. Inactivated
    • 9.1.3. mRNA
    • 9.1.4. Viral Vector
    • 9.1.5. Live Attenuated
    • 9.1.6. Toxoid
    • 9.1.7. Others
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Parenteral
    • 9.2.2. Oral
  • 9.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 9.3.1. Viral Diseases
      • 9.3.1.1. Hepatitis
      • 9.3.1.2. Influenza
      • 9.3.1.3. Human Papillomavirus
      • 9.3.1.4. Herpes Zoster
      • 9.3.1.5. Others
    • 9.3.2. Bacterial Diseases
      • 9.3.2.1. Meningococcal Disease
      • 9.3.2.2. Pneumococcal Disease
      • 9.3.2.3. Diphtheria/Tetanus/Pertussis
      • 9.3.2.4. Others
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital & Retail Pharmacies
    • 9.4.2. Government Suppliers
    • 9.4.3. Others
  • 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Adults Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Recombinant/Conjugate/Subunit
    • 10.1.2. Inactivated
    • 10.1.3. mRNA
    • 10.1.4. Viral Vector
    • 10.1.5. Live Attenuated
    • 10.1.6. Toxoid
    • 10.1.7. Others
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Parenteral
    • 10.2.2. Oral
  • 10.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 10.3.1. Viral Diseases
      • 10.3.1.1. Hepatitis
      • 10.3.1.2. Influenza
      • 10.3.1.3. Human Papillomavirus
      • 10.3.1.4. Herpes Zoster
      • 10.3.1.5. Others
    • 10.3.2. Bacterial Diseases
      • 10.3.2.1. Meningococcal Disease
      • 10.3.2.2. Pneumococcal Disease
      • 10.3.2.3. Diphtheria/Tetanus/Pertussis
      • 10.3.2.4. Others
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital & Retail Pharmacies
    • 10.4.2. Government Suppliers
    • 10.4.3. Others
  • 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Bavarian Nordic
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. GSK plc
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. EMERGENT
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Merck & Co., Inc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Inovio Pharmaceuticals, Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Pfizer Inc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Sanofi
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. CSL
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. AstraZeneca
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Adults Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 2: Global Adults Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 3: Global Adults Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 4: Global Adults Vaccines Market Revenue (USD billion) Forecast, by Viral Diseases, 2021-2034
  • Table 5: Global Adults Vaccines Market Revenue (USD billion) Forecast, by Bacterial Diseases, 2021-2034
  • Table 6: Global Adults Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 7: Global Adults Vaccines Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 8: North America Adults Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 9: North America Adults Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 10: North America Adults Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 11: North America Adults Vaccines Market Revenue (USD billion) Forecast, by Viral Diseases, 2021-2034
  • Table 12: North America Adults Vaccines Market Revenue (USD billion) Forecast, by Bacterial Diseases, 2021-2034
  • Table 13: North America Adults Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 14: North America Adults Vaccines Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 15: Europe Adults Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 16: Europe Adults Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 17: Europe Adults Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 18: Europe Adults Vaccines Market Revenue (USD billion) Forecast, by Viral Diseases, 2021-2034
  • Table 19: Europe Adults Vaccines Market Revenue (USD billion) Forecast, by Bacterial Diseases, 2021-2034
  • Table 20: Europe Adults Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 21: Europe Adults Vaccines Market Revenue (USD billion) Forecast, By Country/Sub-region, 2021-2034
  • Table 22: Asia Pacific Adults Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 23: Asia Pacific Adults Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 24: Asia Pacific Adults Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 25: Asia Pacific Adults Vaccines Market Revenue (USD billion) Forecast, by Viral Diseases, 2021-2034
  • Table 26: Asia Pacific Adults Vaccines Market Revenue (USD billion) Forecast, by Bacterial Diseases, 2021-2034
  • Table 27: Asia Pacific Adults Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 28: Asia Pacific Adults Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 29: Latin America Adults Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 30: Latin America Adults Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 31: Latin America Adults Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 32: Latin America Adults Vaccines Market Revenue (USD billion) Forecast, by Viral Diseases, 2021-2034
  • Table 33: Latin America Adults Vaccines Market Revenue (USD billion) Forecast, by Bacterial Diseases, 2021-2034
  • Table 34: Latin America Adults Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 35: Latin America Adults Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 36: Middle East & Africa Adults Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 37: Middle East & Africa Adults Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 38: Middle East & Africa Adults Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 39: Middle East & Africa Adults Vaccines Market Revenue (USD billion) Forecast, by Viral Diseases, 2021-2034
  • Table 40: Middle East & Africa Adults Vaccines Market Revenue (USD billion) Forecast, by Bacterial Diseases, 2021-2034
  • Table 41: Middle East & Africa Adults Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 42: Middle East & Africa Adults Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Adults Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Adults Vaccines Market Value Share (%), by Type, 2025 & 2034
  • Figure 3: Global Adults Vaccines Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 4: Global Adults Vaccines Market Value Share (%), by Disease Indication, 2025 & 2034
  • Figure 5: Global Adults Vaccines Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 6: Global Adults Vaccines Market Value Share (%), by Region, 2025 & 2034
  • Figure 7: North America Adults Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 8: North America Adults Vaccines Market Value Share (%), by Type, 2025
  • Figure 9: North America Adults Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 10: North America Adults Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 11: North America Adults Vaccines Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 12: North America Adults Vaccines Market Value Share (%), by Disease Indication, 2025
  • Figure 13: North America Adults Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 14: North America Adults Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 15: North America Adults Vaccines Market Value (USD billion), By Country, 2025 & 2034
  • Figure 16: North America Adults Vaccines Market Value Share (%), By Country, 2025
  • Figure 17: Europe Adults Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 18: Europe Adults Vaccines Market Value Share (%), by Type, 2025
  • Figure 19: Europe Adults Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 20: Europe Adults Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 21: Europe Adults Vaccines Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 22: Europe Adults Vaccines Market Value Share (%), by Disease Indication, 2025
  • Figure 23: Europe Adults Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 24: Europe Adults Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 25: Europe Adults Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Adults Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Adults Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 28: Asia Pacific Adults Vaccines Market Value Share (%), by Type, 2025
  • Figure 29: Asia Pacific Adults Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 30: Asia Pacific Adults Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 31: Asia Pacific Adults Vaccines Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 32: Asia Pacific Adults Vaccines Market Value Share (%), by Disease Indication, 2025
  • Figure 33: Asia Pacific Adults Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 34: Asia Pacific Adults Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Asia Pacific Adults Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Adults Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Latin America Adults Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 38: Latin America Adults Vaccines Market Value Share (%), by Type, 2025
  • Figure 39: Latin America Adults Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 40: Latin America Adults Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 41: Latin America Adults Vaccines Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 42: Latin America Adults Vaccines Market Value Share (%), by Disease Indication, 2025
  • Figure 43: Latin America Adults Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 44: Latin America Adults Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 45: Latin America Adults Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Adults Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Adults Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 48: Middle East & Africa Adults Vaccines Market Value Share (%), by Type, 2025
  • Figure 49: Middle East & Africa Adults Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 50: Middle East & Africa Adults Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 51: Middle East & Africa Adults Vaccines Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 52: Middle East & Africa Adults Vaccines Market Value Share (%), by Disease Indication, 2025
  • Figure 53: Middle East & Africa Adults Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 54: Middle East & Africa Adults Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 55: Middle East & Africa Adults Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 56: Middle East & Africa Adults Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 57: Global Adults Vaccines Market Share (%), By Company, 2025